Brustkrebs: Rezidiv, Metastasen, Nachsorge · Skelettszintigraphie, Hot Spot · Thorax-Röntgen Zusammenfassung Hintergrund: Bedingt durch neue Therapieoptionen gibt es derzeit erneut Diskussionen über die Rolle des perioperativen Screenings und regelmäßiger Nachsorgeuntersuchungen bei Brustkrebspatientinnen. Hierbei wird die Rolle von Röntgenuntersuchungen kontrovers diskutiert. Ziel dieser Übersichtsarbeit ist es, den Stellenwert des Röntgen von Brustkrebspatienten perioperativ und in der Nachsorge zu bestimmen. Material und Methoden: Eine Literaturrecherche wurde in Pubmed vorgenommen. Insgesamt wurden 173 Abstracts begutachtet und 27 Orginalarbeiten sowie ein Cochrane Database System Review ausgewertet. Ergebnisse: Röntgenunter-suchungen zum perioperativen Staging sowie in der routinemäßigen Nachsorge asymptomatischer Patienten ergeben keinen Benefit für das erkrankungsfreie Intervall und das Gesamtüberleben, und sind mit einer hohen Falsch-Positiv-Rate verbunden. «Hot Spots» in der Skelettszintigraphie sind meist benigner Genese und bedür-fen häufig weitererführender radiologischer Abklärung ohne Benefit für das Outcome. Schlussfolgerung: Aufgrund des (bisher) nicht nachgewiesenen Benefits und fehlender therapeutischer Konsequenzen sind Röntgen-untersuchungen weder perioperativ noch in der Nachsorge von asymptomatischen Patientinnen indiziert.
Introduction
Currently, there are new public discussions regarding perioperative screening and intensive follow-up of asymptomatic breast cancer (BC) survivors [1, 2] . This is explained by newer treatment options. It is supposed that an early detection and earlier treatment of recurrence would improve the outcome, especially the overall survival (OAS). For the detection of clinically occult metastases, different imaging methods are available, however, most of them are very expensive and not
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Universitäts-Frauenklinik am Klinikum Südstadt, Rostock, Germany widely available. X-ray is an established method in the detection of pulmonary and bone metastases, it is cheap and always available. The aim of the presented literature review is the evaluation of X-ray in the detection of pulmonary and bone metastases in patients without signs of distant tumor spread (cM0) at the time of primary treatment (perioperative staging) and during follow-up of asymptomatic BC survivors, and its role in the further diagnosis of suspicious hot spots in bone scans (BS).
Materials and Methods
PubMed was searched for articles (clinical trials, meta-analyses, randomized controlled trials, and reviews) which studied the impact of BS and Xray in the detection rate of metastases in symptomatic and asymptomatic BC patients, perioperatively and during normal follow-up. Key words used for the search were: bone scan, chest X-ray (CXR), Xray, metastasis, detection rate, breast cancer follow-up, breast cancer, breast, recurrence, hot spot. In total, 173 abstracts were examined in MEDLINE. From these, 27 abstracts and 1 Cochrane database system review thoroughly met the objective. These articles were obtained and reviewed.
Results
Perioperative Screening
With regard to perioperative staging examinations, several studies have conformingly shown that there is no general advantage for low risk BC patients in the detection of distant [4] . A different definition of high risk patients has been established by Ravaioli et al. [5] . According to them, BC patients can be divided into 2 different risk groups: a low risk group containing pT1-3 patients with up to 3 involved lymph nodes, and a high risk group including all patients with more than 3 involved lymph nodes, pT4, and pN2 tumors. Other studies like Myers et al. [6] , Puglisi et al. [7] , and Samant et al. [8] defined similar groups of high and low risk BC patients. Perioperative detection rates for pulmonary and bone metastases are very low in low risk BC patients and are incommensurate with the high costs of staging examinations [9, 10] . In addition to high rate of false positive findings and missing therapeutic consequences, perioperative staging examinations let the patients feel even more insecure and decrease their health-related quality of life [11] . Most authors (table 1) recommended perioperative screening in high risk patients only. However, even in these patients, there is no apparent advantage in the early detection of occult metastases. The only reason for screening these patients is the avoidance of aggressive adjuvant treatment in cases of distant metastases [11] . It is not adequate to define risk profile by tumor size and number of involved lymph nodes. The individual risk is better defined by biological characteristics like endocrine responsiveness, HER2 expression, and epidermal growth factor receptor (EGFR).
Chest X-Ray during Follow-Up of BC Patients
Most studies concerned with regular CXR in follow-up of asymptomatic BC patients were published years ago (table 2). All major studies have shown an insignificant detection rate of distant metastasis and no benefit for OAS [12] [13] [14] . Again, CXR screening is associated with little clinical value, high false positive rates, and high costs [15, 16] . Early detection simply increases the period during which a metastasis is observed and does not add a survival advantage in asymptomatic patients [12-14, 17, 18] . Any treatment option in the situation of asymptomatic metastasis results in a decrease of quality of life. Offering CXR only to symptomatic patients during follow-up, makes a significant difference in the time to detection of metastasis in asymptomatic patients without enlarging the risk of increased OAS [14] . Especially in asymptomatic patients, early detection of metastases would initiate treatment and can easily lead to overtreatment. Up to now, there is no evidence that early detection of advanced disease and imme- tests [19] . As a result, less intensive follow-up strategies based on periodical clinical examinations seem as efficient as more intense surveillance schemes in low risk asymptomatic patients. High false positive rates and lacking therapeutically options are also limitations to intensive follow-up in this patient group. According to literature reviews, a regular follow-up could only be recommended in high risk patients. However, all guidelines [20] [21] [22] [23] do not recommend regular diagnostic follow-up particularly in this high risk group. So far, there are no data showing any OAS benefit of early treatment in clinically asymptomatic patients. A study published by John et al. [24] even indicates an increased risk of BC, particularly in genetically susceptible women, who underwent some form of lowdose radiation like CXR. Taking this into consideration, CXR should be used even more restrictedly. Reduced follow-up strategies for BC can improve quality of life by reducing the anxiety experienced at each follow-up visit [25] .
Chest X-Ray in Symptomatic BC Patients
Regarding the observations of John et al. [24] , one has to also review the usefulness and frequency of CXR in symptomatic patients. The detection rate in symptomatic patients is generally higher than in asymptomatic patients but has no influence on DFS and OAS (table 3) [13, 26] . Whether recurrence was found at the scheduled follow-up visits or between scheduled visits, symptoms were the primary indicator of relapse. Within this symptomatic group, Pivot et al. [13] detected only 10.3% metastases by CXR, indicating a low importance of CXR in symptomatic patients. Approximately 3 times more CXR have to be taken to detect metastases in asymptomatic patients. In addition, it is associated with a high false positive rate [27] . Patients in whom relapse has been falsely suspected are likely to suffer anxiety and derive harm rather than benefit from the X-ray examination.
Chest X-Ray for Further Evaluation of Hot Spots in BC Survivors
BS is accepted as a very sensitive method for the investigation of skeletal metastases, and, despite rapid advances in all imaging modalities, there has been no serious challenge to BS for the detection of skeletal metastasis. Nevertheless, BS should only be considered in symptomatic patients. Table 4 reviews the studies dealing with further evaluation of hot spots in BS. For further evaluation of pathological findings in BS, CXR is still an established procedure. The detection of solitary rib lesion either during perioperative staging or follow-up examinations in BC patients is not uncommon and presents a major diagnostic problem. Single hot spots in a BS are frequently of benign origin and cause a lot of unnecessary radiographic tests and expenses for the health system [16, 28, 29] .The more abnormalities occur in BS, the higher the risk of metastasis [30] . In asymptomatic patients with 1 or 2 abnormalities, most benign changes either remain unchanged or resolve within 12-24 month [31] . For further clarification of these mostly benign hot spots, additional CXR and other radiological tests are necessary [31, 32] . In cancer patients with 1 or 2 new BS abnormalities, correlative radiographs showing a benign abnormality are reliable [31] . Chen et al. [33] showed that direct tumor invasion to the chest wall or skin, 10 or more involved lymph nodes, and no radiotherapy were associated with increased risk of bone metastases whereas a longer time interval between surgery and rib lesion detection and longer persistence of the rib lesions were associated with lower risk of distant metastasis.
Conclusion
With the evidence presented in the synopsis above and the reviewed literature, the following conclusions can be drawn. For low risk BC patients, perioperative X-ray is not indicated. This also applies to routine X-ray and other radiological tests during follow-up in asymptomatic patients, due to no benefit in DFS, OAS, and high costs. A high number of false positive findings with further diagnostic procedures impair the quality of life. Hot spots in BS have to be carefully evaluated. In most cases, they are of benign cause, and the validity of these findings has to be assessed carefully. Due to lacking therapeutic potential, early detection is only valuable if more effective treatment modalities are available, and randomized clinical trials have shown their superiority in asymptomatic detected metastases compared to symptomatic patients.
